
Cyxone Aims to Initiate Phase 2 Clinical Trial with Rabeximod in Covid-19 Patients
Cyxone (publ), a Swedish biotech company dedicated to developing improved treatments for autoimmune diseases, declared that it hopes to initiate a phase 2 clinical trial with Rabeximod in Covid-19 patients.
By
CIO Applications Europe | Tuesday, September 15, 2020

Most people with Covid-19 show only mild symptoms. However, in severely affected patients, the immune system overreacts, triggering a disproportional release of chemokines and cytokines that results in hyper inflammation and severe respiratory failure. There is currently no effective therapy available to fight this potentially lethal condition
FREMONT, CA: Cyxone (publ), a Swedish biotech company dedicated to developing improved treatments for autoimmune diseases, declared that it hopes to initiate a phase 2 clinical trial with Rabeximod in Covid-19 patients. The treatment is intended to decrease the risk of developing severe respiratory symptoms caused by virus-related overactivation of the immune system.
Most people with Covid-19 show only mild symptoms. However, in severely affected patients, the immune system overreacts, triggering a disproportional release of chemokines and cytokines that results in hyper inflammation and severe respiratory failure. There is presently no effective therapy available to fight this potentially lethal condition.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The initiation of Cyxone's clinical development program in Covid-19 patients is based on a discovery of the US scientist and entrepreneur Dr. Kalev Kask, who has recognized the potential of Rabeximod to control the overactivation of the immune system in patients infected with lethal viruses, such as Sars-Cov-2. To acquire and develop all the intellectual features of the Covid-19/Rabeximod project, Cyxone and Dr. Kask entered into a development and investment agreement, as previously communicated on June 10, 2020.
Currently, Cyxone is preparing regulatory applications to allow for initiation of the phase 2 trial in a number of countries in Europe, a process that is facilitated by fast track programs that have been put in place by the authorities to accelerate the development of Covid-19 treatments. The trial will be financed by existing company proceeds and funds from the previously declared directed share issues that are part of the agreement with Kalev Kask.
"As we are currently experiencing one of the most severe pandemics in our lifetime, Cyxone has decided to expand the development of Rabeximod, aiming to prevent Covid-19 patients from developing severe symptoms and avoiding the need of intensive care treatment. A successful outcome of the Phase 2 study would open a range of opportunities for Rabeximod in the area of Covid-19 and other virally induced acute respiratory disorders," stated CEO Tara Heitner.
More in News
Weekly Brief
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from CIO Applications Europe
THANK YOU FOR SUBSCRIBING


